TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Telix Pharmaceuticals ( (AU:TLX) ) has issued an update.
Telix Pharmaceuticals reported strong financial results for the first half of 2025, with a 63% increase in revenue to $390.4 million, driven by strategic investments in commercial infrastructure and R&D. The company is expanding its global manufacturing operations and launching new products, positioning itself for sustainable long-term growth. Despite a loss before tax of $4.8 million due to non-cash finance costs and increased amortization, Telix maintains a positive operating cash flow and continues to invest heavily in its therapeutics pipeline, with significant advancements in clinical trials and product approvals anticipated.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a company operating in the biotechnology industry, focusing on precision medicine and therapeutic solutions. Their primary products include Illuccix and other radiopharmaceuticals, with a market focus on advanced cancer treatments and precision diagnostics.
Average Trading Volume: 1,771,469
Technical Sentiment Signal: Sell
Current Market Cap: A$6B
Learn more about TLX stock on TipRanks’ Stock Analysis page.